Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...